CN-121991902-A - Drug-resistant klebsiella pneumoniae phage vB_ KpnS _YPH3 and application thereof

Abstract

The invention relates to a drug-resistant klebsiella pneumoniae phage vB_ KpnS _YPH3 and application thereof, belonging to the technical field of microorganisms, wherein the phage is preserved in China center for type culture collection (China center for type culture collection), the preservation date is 2025, month and 28, and the preservation number is CCTCC No.20251208; the phage of the invention can effectively lyse the phage which is a special and refractory pathogen of the klebsiella pneumoniae microcolonia mutant with resistance to the pull-tab, and in vitro experiments prove that the phage can completely clear host bacteria in a short time, and the invention provides a brand-new and effective treatment option aiming at the existing antibiotics, especially the SCV infection which is invalid according to the pull-tab treatment, and is hopeful to solve the bottleneck problem in clinical treatment.

Inventors

• ZHENG RUI
• SUN YAHONG
• ZHU LEI
• ZHOU DAN
• MI YI

Assignees

• 云南省第一人民医院
• 昆明理工大学

Dates

Publication Date

20260508

Application Date

20260123

Claims (5)

1. 1. The drug-resistant klebsiella pneumoniae phage vB_ KpnS _YPH3 is characterized in that the phage vB_ KpnS _YPH3 is preserved in China Center for Type Culture Collection (CCTCC) with a preservation date of 2025, 05 month and 28 days and a preservation number of CCTCC No.20251208.
2. 2. Use of phage vb_ KpnS _yph3 as claimed in claim 1 for the preparation of a medicament for the prophylaxis and treatment of drug-resistant klebsiella pneumoniae infected diseases.
3. 3. A phage composition, characterized in that, comprising the phage vB_ KpnS _YPH3 of claim 1.
4. 4. A phage pharmaceutical preparation whose active ingredient comprises the phage of claim 1 or the phage composition of claim 3.
5. 5. Use of phage vb_ KpnS _yph3 according to claim 1 for in vitro inhibition or elimination of a mutant of the microcoloning of eplerenone resistant pneumonitis.

Description

Drug-resistant klebsiella pneumoniae phage vB_ KpnS _YPH3 and application thereof Technical Field The invention belongs to the technical field of microorganisms, and particularly relates to a drug-resistant klebsiella pneumoniae phage vB_ KpnS _YPH3 and application thereof. Background Klebsiella pneumoniae is an important conditional pathogenic bacterium, often causes hospital and community acquired infections such as pneumonia, blood flow infection, urinary tract infection, abdominal cavity infection and the like, and particularly threatens patients with low immunity. Microcolonie phenotype mutants (Small colony variant, SCV) are a special type of bacterial variant characterized by slow growth, microscopic colonies, and are often associated with persistent infections, biofilm formation, and increased tolerance to multiple antibiotics, resulting in difficult clinical treatments and susceptibility to recurrence of the infection. Epigallotin is a novel broad-spectrum tetracycline antibiotic commonly used for treating multiple drug-resistant gram-negative infections including Klebsiella pneumoniae. However, with the increasing clinical use thereof, the emergence and spread of resistant strains (particularly, pull-ring resistant klebsiella pneumoniae, abbreviated ER-KP) has become a serious public health challenge. For ER-KPs, particularly their SCV phenotype, conventional antibiotic treatment regimens tend to fail. SCV is inherently resistant to a variety of antibiotics and is prone to biofilm formation, further impeding antibiotic penetration, leading to chronic, refractory infections. The development of novel antibiotics has long period and high cost, and bacteria can rapidly generate new drug resistance. Phage therapy is an alternative therapy to treat bacterial infections by phage-specific lysis of bacteria. It has the advantages of high host specificity, self proliferation, capability of penetrating biological envelope, uneasiness of causing dysbacteriosis, etc. The separation of phage with high-efficiency lytic ability against specific drug-resistant strains is an effective strategy for solving the problem of antibiotic resistance. At present, no phage and related reports of application thereof are known, which are specially aimed at 'the micro colony mutant of the klebsiella pneumoniae with the resistance to the epothilone'. The invention aims to fill the gap, provides a bacteriophage which can efficiently lyse the multi-drug-resistant bacteria with high retention, and provides a new biological preparation for solving the clinical problem. Disclosure of Invention In order to overcome the problems in the background technology, the invention provides a drug-resistant klebsiella pneumoniae phage vB_ KpnS _YPH3 Klebsiella pneuanoniae phage and application thereof, wherein the phage vB_ KpnS _YPH3 is preserved in China center for type culture collection, the preservation date is 2025, 05 months and 28 days, and the preservation number is CCTCC No.20251208. The invention also provides application of the phage vB_ KpnS _YPH3 in preparing a medicament for preventing and treating drug-resistant klebsiella pneumoniae infection diseases. The present invention also provides a phage composition comprising phage vB_ KpnS _YPH3. The invention also provides a phage pharmaceutical preparation comprising the phage described above or the phage composition described above. The invention also provides application of phage vB_ KpnS _YPH3 in inhibiting or eliminating the micro-colony mutant of the eplerenone drug-resistant Klebsiella pneumoniae in vitro. The invention has the beneficial effects that: The phage of the invention can effectively lyse the phage which is a special and difficult to treat pathogen, namely the Klebsiella pneumoniae microcoloning mutant with resistance to pull-tab, and in vitro experiments prove that the phage can completely clear host bacteria in a short time, provides a brand-new and effective treatment option for the existing antibiotics, especially the SCV infection with failure according to pull-tab treatment, and is hopeful to overcome the bottleneck problem in clinical treatment. The phage of the invention can be used as a green substitute for traditional chemical disinfectants for biological decontamination in hospital environments and high-risk areas. Drawings FIG. 1 shows the form of phage vB_ KpnS _YPH3 of the invention; FIG. 2 is a gene map of phage vB_ KpnS _YPH3 of the invention; FIG. 3 shows colony morphology on kpn11 platelets of example 2 of the invention; FIG. 4 shows the bacteriostasis of kpn11 by the phage of the invention; FIG. 5 is a phage drug susceptibility test result of the invention; FIG. 6 shows the phage lysis of kpn11 according to the invention. Detailed Description In order to make the objects, technical solutions and advantageous effects of the present invention more apparent, the technical solutions of the present invention will be described in detail below, and it is